Skip to content
Recovery & Performance PeptidesRecovery research and practical context
Source comparison

Semax ADHD Focus Attention Research: Comparison of Study Methodologies

| Study Model | Dose & Route | Duration | Primary Outcome | Effect Size | Methodological Limitation | Professional Assessment ||—|—|—|—|—|—|| Russian pediatric open-label (2007) | 200 µg intranasal 2x/day | 30 days | Parent-rated attention improvement | Report

This comparison does not assign a generated winner or score.

  • | Study Model | Dose & Route | Duration | Primary Outcome | Effect Size | Methodological Limitation | Professional Assessment ||—|—|—|—|—|—|| Russian pediatric open-label (2007) | 200 µg intranasal 2x/day | 30 days | Parent-rated attention improvement | Reported as "significant" (no effect size published) | No placebo control, non-validated scales, diagnostic criteria unclear | Suggestive but unverifiable. Replication required || SHR rodent 5-CSRTT (2015) | 50 µg/kg intranasal daily | 21 days | Correct response rate on attention task | +23% vs saline SHR control | Animal model limitations, dose not directly translatable to humans | Strongest mechanistic evidence for attention modulation || Polish healthy volunteer pilot (2018) | 600 µg intranasal daily | 14 days | Reaction time on target detection | 12% faster vs baseline | No control group, unblinded, small n=15 | Pilot-grade data only. Hypothesis-generating || Adult asthenic disorder trial (2010) | 600 µg intranasal daily | 21 days |